Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 10,875 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $21.47, for a total value of $233,486.25. Following the completion of the transaction, the chief operating officer owned 661,332 shares in the company, valued at $14,198,798.04. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Scott Lish also recently made the following trade(s):
- On Thursday, November 20th, Scott Lish sold 25,000 shares of Alphatec stock. The shares were sold at an average price of $19.80, for a total transaction of $495,000.00.
Alphatec Price Performance
NASDAQ ATEC opened at $20.67 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The stock has a market capitalization of $3.07 billion, a PE ratio of -19.88 and a beta of 1.08. Alphatec Holdings, Inc. has a 12-month low of $8.69 and a 12-month high of $22.66. The company has a 50 day moving average price of $18.04 and a two-hundred day moving average price of $14.95.
Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same quarter in the prior year, the business posted ($0.28) EPS. The firm's revenue for the quarter was up 30.4% compared to the same quarter last year. As a group, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have weighed in on the company. Wells Fargo & Company boosted their price target on Alphatec from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Thursday, October 16th. JPMorgan Chase & Co. began coverage on Alphatec in a research note on Friday, October 24th. They issued an "overweight" rating and a $19.00 price objective on the stock. Morgan Stanley set a $23.00 target price on Alphatec in a report on Tuesday, December 2nd. HC Wainwright upped their target price on Alphatec from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, October 31st. Finally, Needham & Company LLC lifted their price target on shares of Alphatec from $16.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, October 31st. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.20.
Check Out Our Latest Analysis on ATEC
Institutional Trading of Alphatec
Several hedge funds have recently added to or reduced their stakes in ATEC. Nuveen LLC bought a new position in Alphatec in the 1st quarter worth approximately $135,874,000. Vanguard Group Inc. boosted its position in shares of Alphatec by 2.4% in the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company's stock valued at $99,091,000 after acquiring an additional 158,295 shares during the period. American Century Companies Inc. grew its stake in shares of Alphatec by 2.6% in the third quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company's stock worth $92,133,000 after acquiring an additional 159,330 shares during the last quarter. Royal Bank of Canada increased its position in Alphatec by 10.8% during the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock worth $35,773,000 after acquiring an additional 342,656 shares during the period. Finally, Geode Capital Management LLC increased its position in Alphatec by 7.4% during the second quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company's stock worth $29,946,000 after acquiring an additional 185,297 shares during the period. Institutional investors own 66.35% of the company's stock.
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
